Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Extended-Release Drugs Market Growth in 2025?

There has been significant expansion in the market size of extended-release drugs in the past few years. The market is expected to rise from a value of $63.11 billion in 2024 to reach $70.28 billion in 2025, indicating a compound annual growth rate (CAGR) of 11.4%. Factors contributing to this growth during the historical period include improvements in patient compliance, increased prevalence of chronic diseases, enhanced efficacy, strategic patent protection, and the introduction of biodegradable implants.

What Is the Forecast for the Extended-Release Drugs Market Size Through 2029?

In the coming years, the extended-release drugs market is predicted to witness swift expansion. The market size is projected to reach $113.05 billion by 2029, with a compound annual growth rate (CAGR) of 12.6%. Factors contributing to this growth during the forecast period include the introduction of personalized medicine, a focus on patient-centric drug development, an increased prevalence of lifestyle-related diseases, drug repurposing, and worldwide access to extended-release treatments. Key trends anticipated within the forecast period comprise pharmaceutical innovation, advances in drug delivery systems, and nanotechnology, the use of 3d printing in drug formulation, artificial intelligence integration, and environmental sustainability.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp

What are the Key Market Players in Extended-Release Drugs Market and How They’re Evolving?

Major companies operating in the extended-release drugs market include Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc.

What Are the Primary Growth Drivers in the Extended-Release Drugs Market?

The accelerated growth of the extended-release drug market is predicted to be driven by a rising prevalence of chronic illnesses. Chronic conditions are characterized as ailments that persist for 12 months or more, requiring ongoing medical attention, limiting daily activities, or both. Illnesses such as heart disease, cancer, obesity, and diabetes fall into this category. Extended-release drug delivery systems have been developed with the intention to maintain a steady medication level in the body over a prolong period. This method assists in sustaining a stable therapeutic impact and circumvents the inconsistency in drug levels that may occur with immediate-release medications. Case in point, the National Center for Biotechnology Information (NCBI), a United States based National Library of Medicine, forecasted in January 2023 that by 2050, there will be an anticipated 99.5% increase in the amount of people aged 50 and above suffering from at least a single chronic disease, increasing the number to 142.66 million. Hence, the escalating prevalence of chronic conditions is propelling the expansion of the extended-release drug market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12675&type=smp

What Are the Leading Segments in the Global Extended-Release Drugs Industry?

The extended-release drugs market covered in this report is segmented –

1) By Type: Sustained Release Drug, Controlled Release Drug

2) By Mode: Over-The-Counter, Prescription

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores

Subsegments:

1) By Sustained Release Drug: Matrix Systems, Coating Systems

2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems

What Are the Key Market Trends in the Extended-Release Drugs Industry?

The extended-release drug market is currently experiencing a surge in product innovation, a trend receiving increased attention. Key players in this market are creating unique products in order to maintain their market standing. To illustrate, in July 2022, Zydus Pharmaceuticals (USA) Inc., a corporation specializing in generic pharmaceutical production, introduced Topiramate extended-release capsules for controlling epilepsy. Previously, the US Food and Drug Administration (USFDA) had authorized the company to commercialize Topiramate extended-release capsules, USP 25 mg, 50 mg, and 100 mg. This made them the first enterprise in the US to receive final approval and launch this product. The Topiramate extended-release tablets have approval for use in cases of partial onset or primary generalized tonic-clinic seizure.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report

What Is the Regional Outlook for the Extended-Release Drugs Market?

North America was the largest region in the extended-release drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12675

This Report Delivers Insight On:

1. How big is the extended-release drugs market, and how is it changing globally?

2. Who are the major companies in the extended-release drugs market, and how are they performing?

3. What are the key opportunities and risks in the extended-release drugs market right now?

4. Which products or customer segments are growing the most in the extended-release drugs market?

5. What factors are helping or slowing down the growth of the extended-release drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model